You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="http://windows.microsoft.com/de-de/windows/end-support-help">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

News

Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides

18. September 2017
NUMAFERM makes the production of peptides more efficient Investment strengthens Evonik’s growth engines Health & Care and Specialty Additives at Evonik New technical applications are becoming realistic for the first time Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was More …

Reactive Robotics GmbH is on track

8. September 2017
Clinical validation, market entry in Germany and further countries secured by second investment round with existing and new investors Founded in 2015 in Munich, Reactive Robotics GmbH is a medical device start-up with the corporate objective to provide the best possible Very Early Mobilization (VEM) to intensive care patients as early as 24 hours after hospital admission, directly in the More …

MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology

6. September 2017
MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)), and Rigontec today announced that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Under the terms More …

AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round

5. September 2017
 Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund Funds will be used to support: Clinical development of lead vaccine (ATP128) for colorectal cancer through to clinical proof-of-concept Further development of KISIMA technology platform for therapeutic tumour vaccination AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed More …

Crowdfunding triggers Capital Increase of 800,000 Euros at Rodos Biotarget

18. August 2017
After his initial crowd investment, medical entrepreneur and business angel Otto H. Gies invests in the biopharmaceutical company via direct shareholding. Rodos Biotarget is the first German life-science company to initiate crowdfunding campaigns via two crowd platforms. In 2016, a first round took place with Seedmatch, and a current financing round is running with aescuvest. With this approach, in addition More …

Neu-Ulm-based medical device producer and High-Tech Gründerfonds found spin-off Zimmer BioTech: New therapy to combat skin cancer

9. August 2017
In the field of dermatology, Zimmer MedizinSysteme GmbH, a company based in Neu-Ulm (southern Germany), has long been the global market leader for cryotherapy products. In founding the spin-off Zimmer BioTech, the company is now taking another step forward and utilising its wealth of experience to treat skin cancer. Together with High-Tech Gründerfonds (HTGF), the medical device producer is investing More …

Specialty biotech company Advanced Enzymes acquires HTGF Portfolio company evoxx technologies

1. August 2017
The industrial biotechnology company evoxx technologies GmbH has become a part of the leading specialty biotech company Advanced Enzyme Technologies Limited. Both companies announced that they have entered into a binding agreement about the acquisition of 100% stake in evoxx technologies. evoxx technologies is proud to announce that it will become part of the global enzyme manufacturing company Advanced Enzyme More …

High-Tech Gründerfonds (HTGF) and MBG invest in stimOS’ Mimicking Bone Technologies: Constance-based Start-Up Company gains HTGF and MBG as investors

27. July 2017
German HTGF acts as seed investor at stimOS GmbH located in Constance: Together with MBG, Baden-Württemberg (MBG), the seed stage investor provides 720,000 euros for further development and approval of stimOS’ patented Mimicking Bone Technology (MBT). To ensure best possible recovery for the patient and achieve a pain-free life after surgery, stimOS GmbH has developed a unique biochemical procedure that More …

Eight science teams give presentations at 3rd Munich Life Science Pitch Day at IZB – Start-ups profit from being in close contact with the venture capital scene

6. July 2017
High-Tech Gründerfonds, Bayer Pharma AG, Merck KGaA and the Innovation and Startup Center for Biotechnology (IZB) hosted the 3rd Munich Life Science Pitch Day at the IZB. Eight start-up teams had the opportunity to present their pioneering projects in front of 15 renowned venture capital and pharmaceutical companies. Among the prominent names taking part were MIG Fonds, Forbion Capital Partners, More …

Focus on innovative medical aids: BVMed, Earlybird, High-Tech Gründerfonds, and BIOCOM AG publish „MedTech Radar 8″

The medical aids market in Germany is worth billions, and will continue to grow – fuelled by the demographic change. Together with the possibilities of digitalisation and technological innovation such as 3D-printing, this market enables individual solutions as well as completely novel business models. Nevertheless, due to budgetary constrictions as well as strict legal regulations it is particularly challenging for More …